Oral+MS+Drugs

=
- Treatment with laquinimod as comapred with placebo was associated with a modest reduction in the mean annualized relapse rate (0.30 vs 0.38, P=0.002) and with a reduction in the risk of confirmed disability progression (11.1% vs 15.7%, P=0.01).=====

=
- results: both doses of fingolimod reduced relapse rate, risk of disability progression, and MRI-related measures (new or enlarged lesions on T2, gad-enhancing lesions, and braind-voume loss) at 2 years=====

TRANSFORMS: Cohen et al, "Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis." NEJM 2010. [|PUBMED]
- double-blind RCT - randomized to oral fingolimod 0.5mg daily, 1.25mg daily, or IM interferon beta-1a 30 mcg weekly - N=1292 - relapsing remitting MS, recent history of at least 1 relapse - primary outcome: annualized relapse rate - secondary outcomes: number of new or enlarged lesions on T2-weighted MRI, progression of disability - results: annualized relapse rate was 0.20 in 1.25mg group, 0.16 in 0.5mg group, 0.33 in interferon group (P<0.001 for both comparisons). No differences in progression of disability.